Preparation, optimization and characterization of chitosan-coated for solubility enhancement of Furosemide: A model BCS IV drug

Document Type : Research article


1 Department of Pharmaceutics, School of Pharmacy, Shahid Beheshti University of medical Sciences, Tehran, Iran.

2 Department of Pharmaceutics, School of Pharmacy, Shiraz University of medical Sciences, Shiraz, Iran.

3 Department of Pharmaceutics, School of Pharmacy, Zanjan University of medical Sciences, Zanjan, Iran.

4 Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.


Most of drugs are administered orally and they must be absorbed from gastrointestinal tract for systemic effect. Generally drug molecules be dissolved in GI fluids before absorption. Solubility and permeability of drugs are considered as two parameters in biopharmaceutical classification system (BCS). Many researches performed to change permeability and solubility of drugs to improve abruption and bioavailability of them. Lipidic nanocarriers such as nanoliposomes are one approach to dissolve poorly water soluble drugs. Furosemide (FMD) as a typical molecule in BCS IV has low solubility and permeability. Thermodynamically, molecules of FMD could stay in the space of liposomal membrane. In this study effective parameters to preparation of nanoliposomes coated by chitosan (CCLs) were screened optimized by experimental design. Particle size, polydispersity index and surface potential of optimized CCLs have 155.8 ±3.5 nm, 0.229±0.022 and 25.2±3.5 mV, respectively. FMD was loaded in optimized CCLs 98.94±0.7%. Size of CCLs have verified by atomic force electron microscope. CCLs loaded by FMD were dried and in vitro study was performed to test release of FMD from powder. Results showed that solubility and dissolution of FMD increased by loading in CCLs in comparison to crystalline FMD and physical mixture of FMD and materials of CCLs.

Graphical Abstract

Preparation, optimization and characterization of chitosan-coated for solubility enhancement of Furosemide: A model BCS IV drug


Main Subjects

(1) Amidon GL, Lennernas H, Shah VP and CrisonJR. A Theoretical basis for a biopharmaceutic drugclassification: The correlation of in-vitro drugproduct dissolution and in-vivo bioavailability.Pharm. Res. (1995) 12: 413-20.
(2) Tsume Y, Matsui K, Searls AL, Takeuchi S, AmidonGE, Sun D and Amidon GL. The impact ofsupersaturation level for oral absorption of BCS classIIb drugs, dipyridamole and ketoconazole, using invivo predictive dissolution system: GastrointestinalSimulator (GIS). Eur. J. Pharm. Sci. (2017) 102:126–39.
(3) Tsume Y, Mudie DM, Langguth P, Amidon GE andAmidon GL. The biopharmaceutics classificationsystem: subclasses for in-vivo predictive dissolution(IPD) methodology and IVIVC. Eur. J. Pharm. Sci.(2014) 57: 152–63.
(4) Tsume Y, Takeuchi S, Matsui K, Amidon GE andAmidon GL. In-vitro dissolution methodology, minigastrointestinal simulator (mGIS), predicts better invivo dissolution of a weak base drug, dasatinib. Eur.J. Pharm. Sci. (2015) 76: 203–12.
(5) Zur M, Hanson AS and Dahan A. The complexity ofintestinal permeability: Assigning the correct BCSclassification through careful data interpretation.Eur. J. Pharm. Sci. (2014) 61: 11–7.
(6) Zakeri-Milani P, Barzegar-Jalali M, Azimi M andValizadeh H. Biopharmaceutical classification ofdrugs using intrinsic dissolution rate (IDR) and ratintestinal permeability. Eur. J. Pharm. Biopharm.(2009) 73: 102–6.
(7) Skelly JP, Amidon GL, Barr WH, Benet LZ, CarterJE, Robinson JR, Shah VP and Yacobi A. In-vitro andin-vivo testing and correlation for oral controlled/modified release dosage forms. Report of the 2ndworkshop held december 1988, Washington, Dc,U.S.A. J. Control Release. (1990) 14: 95-106.
(8) Hens B, Sinko PD, Job N, Dean M, Al-Gousous J andSalehi N. Formulation predictive dissolution (fPD)testing to advance oral drug product development:An introduction to the US FDA funded ‘21st CenturyBA/BE’ project. Int. J. Pharm. (2018) 548: 120–7.
(9) Nagabandi V, Chandragiri AK, Thota S and KatakamP. Enhancement of dissolution rate of naproxen bylipid based solid dispersions. J. Pharm. Sci. Res.380Optimized chitosan-coatedliposomes loaded by furosemide(2014) 6: 78–82.
(10) Williams HD, Trevaskis NL, Charman SA, ShankerRM, Charman WN, Pouton CW and PorterCJH. Strategies to address low drug solubility indiscovery and development. Pharmacol. Rev.(2013) 65: 315–499.
(11) Horter D and Dressman JB. Influence ofphysicochemical properties on dissolution of drugsin the gastrointestinal tract. Adv. Drug Deliv. Rev.(1997) 25: 3–14.
(12) Sun J, Wang F, Sui Y, She Zh, Zhai W, Wang Chand Deng Y. Effect of particle size on solubility,dissolution rate, and oral bioavailability: evaluationusing coenzyme Q10 as nakednanocrystals. Int. J.Nanomedicine. (2012) 7: 5733-44.
(13) Li X, Uehara S, Sawangrat K, Morishita M,Kusamori K, Katsumi H, Sakane T and YamamotoA. Improvement of intestinal absorption ofcurcumin by cyclodextrins and the mechanismsunderlying absorption enhancement. Int. J. Pharm.(2018) 535: 340–9.
(14) Liu T, Wan X, Luo Zh, Liu Ch, Quan P, Cun D andFang L. A donepezil/cyclodextrin complexationor4dispersible film: Effect of cyclodextrin on tastemasking based on dynamic process and in-vivodrug absorption. Asian J. Pharm. Sci. (2018) 1–10.
(15) Eerdenbrugh BV, Martens JA, Speybroeck MV,Mols R, Houthoofd K, Froyen L, Humbeeck JV,Augustijns P and Mooter GVd. Itraconazole/TPGS/Aerosil 200 solid dispersions characterization,physical stability and in-vivo performance. Eur. J.Pharm. Sci. (2009) 38: 270–8.
(16) Wilson V, Lou X, , Osterling DJ, Stolarik DF,Jenkins G, Gao W, Zhang GGZ and Taylor LS.Relationship between amorphous solid dispersionin-vivo absorption and in-vitro dissolution: phasebehavior during dissolution, speciation, andmembrane mass transport. J. Control. Release.(2018) 292: 172–82.
(17) Jermain SV, Brough Ch and Williams RO.Amorphous solid dispersions and nanocrystaltechnologies for poorly water-soluble drugdelivery–An update. Int. J. Pharm. (2018) 535:379–92.
(18) Zhaojie M, Jingkai G, Ming Zh, Shengnan W,Xiaojia B, Hatch GM and Li Ch. Amorphous soliddispersion of berberine with absorption enhancerdemonstrates a remarkable hypoglycemic effectvia improving its bioavailability. Int. J. Pharm.(2014) 467: 50–9.
(19) Medarević D, Cvijić S and Ibrić S. Assessingthe potential of solid dispersions to improvedissolution rate and bioavailability of valsartan: invitro-in-silico approach. Eur. J. Pharm. Sci. (2018)124: 188–98.
(20) Ewing AV, Wray PS, Clarke GS and Kazarian SG.Evaluating drug delivery with salt formation:studied Drug disproportionation in situ by ATRFTIR imaging and Raman mapping. J. Pharm.Biomed. Anal. (2015) 111: 248–56.
(21) Serajuddin ATM. Salt formation to improve drugsolubility. Adv. Drug Deliv. Rev. (2007) 59: 603 –16.
(22) Tran PHL, Tran TTD and Lee BJ. Enhancedsolubility and modified release drugs of poorlywater-soluble via self-assembled gelatin–oleic acidnanoparticles. Int. J. Pharm. (2013) 455: 235–40.
(23) Leuner Ch and Dressman J. Improving drugsolubility for oral delivery using solid dispersions.Eur. J. Pharm. Biopharm. (2000) 50: 47-60.
(24) Junyaprasert VB and Morakul B. Nanocrystalsfor enhancement of oral bioavailability of poorlywater-soluble drugs. Asian J. Pharm. Sci. (2015)10: 13-23.
(25) Ge L, Jiang L, He X, Zhang Y, Zhang Y, Chai F,Webster TJ and Zheng Ch. A dabigatran etexilatephospholipid complex nanoemulsion system forfurther oral bioavailability by reducing drugleakage in the gastrointestinal tract. Nanomedicine(2018) 14: 1455–64.
(26) Desai J and Thakkar H. Enhanced oralbioavailability and brain uptake of Darunavir usinglipid nanoemulsion formulation. Colloids Surf. BBiointerfaces (2019) 175: 143–149.
(27) Gao Y, Qi X, Zheng Y, Ji H, Wu L, Zheng N andTang J. Nanoemulsion enhances α-tocopherolsuccinate bioavailability in rats. Int. J. Pharm.
(2016)515: 506–14.
(28) Li H, Zhao XB, Ma Y, Zhai GX, Li LB and LouHX. Enhancement of gastrointestinal absorption ofquercetin by solid lipid nanoparticles. J. ControlRelease (2009) 133: 238–44.
(29) Zhao M, Lee SH, Song JG, Kim HY and Han HK.Enhanced oral absorption of sorafenib via the layerby-layer deposition of a pH-sensitive polymer andglycol chitosan on the liposome. Int. J. Pharm.(2018) 544: 14–20.
(30) Cui M, Wu W, Hovgaard L, Lu Y, Chen D and QiJ. Liposomes containing cholesterol analoguesof botanical origin as drug delivery systems toenhance the oral absorption of insulin. Int. J.Pharm. (2015) 489: 277–84.
(31) Agarwal S, Muniyandi P, Maekawa T and Kumar DS.Vesicular systems employing natural substances aspromising drug candidates for MMP inhibition inglioblastoma: A nanotechnological approach. Int.J. Pharm. (2018) 551: 339–61.
(32) Wang WX, Feng ShS and Zheng CH. A comparison 381Moslehi M et al. / IJPR (2020), 19 (1): 366-382between conventional liposome and drugcyclodextrin complex in liposomesystem. Int. J.Pharm. (2016) 513: 387-92.
(33) Pu C, Tang W, Li X, Li M and Sun Q. Stabilityenhancement efficiency of surface decoration oncurcumin-loaded liposomes: Comparison of guargum and its cationic counterpart. Food Hydrocoll.(2019) 87: 29-37.
(34) Cortesi R, Esposito E, Gambarin S, Telloli P,Menegatti E and Nastruzzi C. Preparation ofliposomes by reverse-phase evaporation using
alternative organic solvents. J. Microencapsul.(1999) 16: 251-6.
(35) Gregoriadis G, Da Silva H and Florence AT. Aprocedure for the efficient entrapment of drugs indehydration-rehydration liposomes (DRVs). Int. J.Pharm. (1990) 65: 235-42.
(36) Kawano K, Takayama K, Nagai T and Maitani Y.Preparation and pharmacokinetics of pirarubicinloaded dehydration–rehydration vesicles. Int. J.Pharm. (2003) 252: 73–9.
(37) Stano P, Bufali S, Pisano C, Bucci F, Barbarino M,Santaniello M, Carminati P and Luisi PL. NovelCamptothecin analogue (Gimatecan)-containingliposomes prepared by the ethanol injection method. J. Liposome Res. (2004) 14: 87–109.
(38) Ran R, Middelberg APJ and Zhao CX. Microfluidicsynthesis of multifunctional liposomes for tumourtargeting. Colloids Surf. B Biointerfaces (2016)148: 402–10.
(39) Chiba M, Miyazaki M and Ishiwata Sh. Quantitative analysis of the lamellarity of giant liposomes prepared by the inverted emulsion method. Biophys. J. (2014) 107: 346–54.
(40) Li M, Du Ch, Guo N, Teng Y, Meng X, Sun H, LiSh, Yu P and Galons H. Composition design andmedical application of liposomes. Eur. J. Med.Chem. (2019) 164: 640-653.
(41) Güven A, Ortiz M, Constanti M and O’Sullivan CK.Rapid and efficient method for the size separationof homogeneous fluorescein-encapsulatingliposomes. J. Liposome Res. (2009) 19: 148–54.
(42) Woodle MC. Sterically stabilized liposometherapeutics. Adv. Drug Del. Rev. (1995) 16: 249-65.
(43) Saesoo S, Bunthot S, Sajomsang W, Gonil P, PhunpeeS, Songkhum P, Laohhasurayotin K, WutikhunT, Yata T, Ruktanonchai UR and Saengkrit N.Phospholipid-chitosan hybrid nanoliposomespromoting cell entry for drug delivery againstcervical cancer. J. Colloid Interface Sci. (2016)480: 240–8.
(44) Socaciu C, Lausch C and Diehl HA. Carotenoids inDPPC vesicles: membrane dynamics. Spectrochi.Ac. Part A. (1999) 55: 2197-2289.
(45) Tan Ch, Feng B, Zhang X, Xia W and Xia Sh.Biopolymer-coated liposomes by electrostaticadsorption of chitosan (chitosomes) as noveldelivery systems for carotenoids. Food Hydrocoll.
(2016) 52: 774-84.
(46) Zhou F, Xu T, Zhao Y, Song H, Zhang L, Wu Xand Lu B. Chitosan-coated liposomes as deliverysystems for improving the stability and oralbioavailability of acteoside. Food Hydrocoll.(2018) 83: 17-24.
(47) Palazzo C, Dogne JM, Laloy J, Delvigne AS, NysG, Fillet M, Pequeux Ch, Foidart JM, Evrard B andPiel G. Development of injectable liposomes anddrug-in-cyclodextrin-in-liposomeformulationsencapsulating estetrol to prevent cerebral ischemiaof premature babies. Eur. J. Pharm. Sci. (2019)127: 52–9.
(48) Li X, Anton N, Arpagaus C, Belleteix F andVandamme TF. Nanoparticles by spray dryingusing innovative new technology: The Büchi NanoSpray Dryer B-90. J. Control. Release. (2010) 147:304–10.
(49) Lo YL, Tsai JC and Kuo JH. Liposomes anddisaccharides as carriers in spray-dried powderformulations of superoxide dismutase. J. ControlRelease. (2004) 94: 259 – 72.
(50) Chen KH, Di Sabatino M, Albertini B, PasseriniN and Kett VL. The effect of polymer coatings on physicochemical properties of spray-driedliposomes for nasal delivery of BSA. Eur. J.Pharm. Sci. (2013) 50: 312–22.(51 Salade L, Wauthoz N, Vermeersch M, Amighi K andGoole J. Chitosan-coated liposome dry-powderformulations loaded with ghrelin for nose-to-braindelivery. Eur. J. Pharm. Biopharm. (2018) 129:257–66.
(52) Darandale SS and Vavia PR. Design of agastroretentive mucoadhesive dosage form offurosemide for controlled release. Act Pharm. Sin.B. (2012) 2: 509–517.
(53) Shariare MH, Altamimi MA, Marzan AL, TabassumR, Jahan B, Reza HM, Rahman M, Ahsan GU andKaz M. In-vitro dissolution and bioavailabilitystudy of furosemide nanosuspension preparedusing design of experiment (DoE). Saudi Pharm.J. (2019) 27: 96–105.
(54) Quinn PJ. Is the Distribution of α-tocopherol inmembranes consistent with its putative functions?Biochemistry (2004) 69: 58-66.
(55) Smith EA and Dea PK. Differential scanningcalorimetry studies of phospholipid membranes:the interdigitated gel phase. In: Applicationsof Calorimetry in a Wide Context–DifferentialScanning Calorimetry, Isothermal Titration 382Optimized chitosan-coated liposomes loaded by furosemideCalorimetry and Microcalorimetry. 1st edition,InTech, Rijeka (Croatia) (2013).
(56) Vanic´Z, Planinšek O, Škalko-Basnet N and Tho I.Tablets of pre-liposomes govern in situ formationof liposomes: Concept and potential of the noveldrug delivery system. Eur. J. Pharm. Biopharm.(2014) 88: 443–54.
(57) Radwan SS, Sokar MS, Abdelmonsif DA and ElKamel H. Mucopenetrating nanoparticles forenhancement of oral bioavailability of furosemide:in-vitro and in-vivo evaluation/sub-acute toxicity study. Int. J. Pharm. (2017) 526: 366–79.